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Influenza vaccination remains the best strategy for the prevention of influenza virus-related 
disease and reduction of disease severity and mortality. However, there is large individual 
variation in influenza vaccine responses. In this study, we investigated the effects of gen-
der, age, underlying diseases, and medication on vaccine responses in 1,852 Icelanders 
of broad age range who received trivalent inactivated influenza virus vaccination in 2012, 
2013, or 2015. Hemagglutination inhibition (HAI) and microneutralization (MN) titers were 
measured in pre- and post-vaccination sera. Of the variables tested, the strongest asso-
ciation was with level of pre-vaccination titer that explained a major part of the variance 
observed in post-vaccination titers, ranging from 19 to 29%, and from 7 to 21% in fold 
change (FC), depending on the strain and serological (HAI or MN) analysis performed. 
Thus, increasing pre-vaccination titer associated with decreasing FC (P = 1.1 × 10−99–
8.6  ×  10−30) and increasing post-vaccination titer (P  =  2.1  ×  10−159–1.1  ×  10−123). 
Questionnaires completed by 87% of the participants revealed that post-vaccination 
HAI titer showed association with repeated previous influenza vaccinations. Gender had 
no effect on vaccine response whereas age had a strong effect and explained 1.6–3.1% 
of HAI post-vaccination titer variance and 3.1% of H1N1 MN titer variance. Vaccine 
response, both fold increase and seroprotection rate (percentage of individuals reaching 
HAI ≥ 40 or MN ≥ 20), was higher in vaccinees ≤37 years of age (YoA) than all other 
age groups. Furthermore, a reduction was observed in the H1N1 MN titer in people ≥63 
YoA, demonstrating a decreased neutralizing functionality of vaccine-induced antibodies 
at older age. We tested the effects of underlying autoimmune diseases, asthma and 
allergic diseases and did not observe significant associations with vaccine responses. 
Intake of immune modulating medication did not show any association. Taken together, 
our results show that previous encounter of influenza vaccination or infection, reflected 
in high HAI and MN pre-vaccination titer has the strongest negative effect on vaccine 
responses measured as FC and the strongest positive effect on post-vaccination titer. 
Increasing age had also an effect but not gender, underlying disease or medication.
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inTrODUcTiOn
The influenza virus causes 3–5 million cases of severe illness 
each year resulting in 250,000–500,000 deaths, most of which 
occur in elderly people [≥65 years of age (YoA)] (1). Vaccination 
is the best preventative measure against influenza illness and 
the World Health Organization (WHO) recommends annual 
vaccinations for high-risk groups; pregnant women, children 
6 months–5 YoA, elderly individuals (≥65 YoA), individuals with 
chronic medical conditions and health-care workers (1). There is 
large individual variation in influenza vaccine responses. Factors 
that have been associated with impaired immune responses to 
influenza vaccinations include age, gender, health status of vac-
cine recipients, prior influenza vaccinations, and obesity (2, 3), 
and various immunomodulators have been reported to influence 
immune responses to vaccines (4–7). We therefore decided to 
investigate influenza vaccine responses in unselected Icelandic 
vaccinees of a broad age range and health conditions.
The trivalent inactivated influenza vaccine (TIV) used in this 
study contains hemagglutinin (HA) surface glycoprotein from 
two influenza A strains (H1N1 and H3N2) and one influenza 
B strain (either Yamagata or Victoria lineage). Vaccine-induced 
hemagglutin (HA) titers are widely accepted as a correlate of 
protection against influenza illness and are measured by the 
ability of HA-specific antibodies to block N-acetylneuraminic 
acid mediated viral agglutination of red blood cells using a 
hemagglutination inhibition (HAI) assay (8, 9). Based on this, 
seroprotection has been defined as HAI antibody titers ≥1:40 
post-vaccination and the proportion of vaccinees achieving this 
titer are referred to as seroprotection rate. Following vaccination, 
the seroprotection rate should be >70% for adults 18–60  YoA 
and >60% for adults >60 YoA. In contrast to HAI titers that only 
measure the capacity of blocking the receptor binding of the 
virus to its host cell, microneutralization (MN) assays are based 
on the use of infectious doses of influenza virus in vitro thereby 
measuring functional antibodies that block entry of the virus 
into cells, fusion of the virus HA to the host cell membrane, and 
internalization of the virus. In addition to measuring antibodies 
capable of neutralizing the strain specific and immunodominant 
head domain, MN have been shown to detect antibodies directed 
to the conserved stalk of HA that could give rise to a broad protec-
tion against different strains of influenza A virus (10). Anti-stalk 
antibodies have been shown to be superior inducers of cytotox-
icity of infected cells compared with anti-head antibodies in a 
mouse model and this effect was dependent on interaction with 
Fc receptors for IgG (FcγRs) (11). However, due to the higher cost 
and labor of MN compared with HAI measurements, HAI is still 
more widely used than MN. In this study, we measured both HAI 
and MN for H1N1 in all pre- and post-vaccination samples, as 
well as in a subset of the vaccinees (n = 336) for the other strains 
and compared the two readouts.
Due to the high-mutation rate of the influenza virus, the 
vaccine components need to be frequently changed to match the 
circulating virus strains (12). However, the potential antigenic 
mismatch does not account for all of the observed differences in 
influenza vaccine efficacy between years. In addition to reported 
risk factors for poor vaccine responses, variation in human 
leukocyte antigen (13) and other host genetic factors may play 
a role (14).
In addition to following WHO’s recommendations regarding 
the annual influenza vaccination in Iceland, many companies 
offer their staff annual influenza vaccinations, even if they are 
not in any of the risk groups. In this study, volunteers scheduled 
for influenza vaccination were recruited at over 70 work places 
and two nursing homes in the Reykjavik area when the annual 
influenza vaccination was offered, securing a broad age range 
independent of health status, and thus both risk and non-risk 
groups. Furthermore, we received information regarding pre-
scribed medicines as well as diagnosis of asthma allergic and 
autoimmune diseases for all the study participants.
The main objective of this study was to evaluate the association 
of age, gender, influenza-specific pre-vaccination immune status, 
underlying diseases, and medication on immune responses to a 
seasonal TIV in unselected Icelanders of a broad age during three 
influenza seasons 2012–2013, 2013–2014, and 2015–2016.
We found that previous influenza virus encounter measured 
by high-pre-vaccination titer showed strong negative asso-
ciation with fold change (FC) levels whereas it showed posi-
tive association with the post-vaccination titer. Furthermore, 
increased age associated with vaccine responses, although to 
less extent than pre-vaccination titer. However, gender, under-
lying diseases, and immunomodulatory medication evaluated 
in this heterogeneous group of vaccinees did not significantly 
affect vaccine responses.
MaTerials anD MeThODs
Participants and study Design
A total of 1,852 volunteers agreed to participate in the study 
and were eligible during October–November in the years 
2012 (n =  565), 2013 (n =  711), and 2015 (n =  577). Age of 
the vaccinees ranged from 20 to 103 YoA, 46% men and 55% 
women. Informed consent and pre-vaccination blood samples 
were obtained by staff of the Patient Recruitment Center (PRC) 
just before the participants received their annual influenza 
vaccination (administered by health-care workers) that they 
had signed up for either at their work places or nursing homes. 
Four weeks later (day 28 ± 3 days), the staff of the PRC went 
back to the workplaces and nursing homes to collect a post-
vaccination blood sample. All participants signed informed 
consent. This study was carried out in accordance with the 
recommendations of National Bioethics Committee (NBC) of 
Iceland with written informed consent from all subjects. All 
subjects gave written informed consent in accordance with 
the Declaration of Helsinki. The protocol was approved by the 
NBC of Iceland (Approval no. VSN-12-153_VSNb2012090016- 
03-12). The study was reported to the Data Protection Authority 
of Iceland (ref. S5936/2012) that also approved access to data 
from the participant’s medical records (PV_2012091015T) 
from Landspitali, the National University Hospital of Iceland 
(1990–2016), and existing data at deCODE genetics. Diagnosis 
of autoimmune diseases we searched for included: ankylosing 
spondylitis, inflammatory bowel disease, multiple sclerosis, 
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myasthenia gravis, primary biliary cirrhosis, psoriasis, psoriatic 
arthritis, rheumatoid arthritis, systemic lupus erythematosus, 
systemic sclerosis, type 1 diabetes, vitiligo, Sjögren’s syndrome, 
and autoimmune thyroiditis. Diagnosis of asthma and allergic 
diseases we searched for included: asthma, allergic rhinitis, ana-
phylaxis, angioedema, chronic sinusitis, nasal polyps, urticaria, 
and atopic dermatitis. 1,611 of the participants (87%) answered 
questionnaires on general health and lifestyle. Information of 
drug prescription for each of the participants was retrieved from 
the Directorate of Health Prescription Database (2003–2016) 
with approval of the NBC. ATC codes of drugs tested for are 
listed in Table S1 in Supplementary Material. The personal 
identities of the participants data and biological samples were 
encrypted using the Identity Protection System, a third-party 
encryption system approved, and monitored by the Icelandic 
Data Protection Authority.
Vaccines
Study participants were vaccinated with Vaxigrip® (Sanofi-
Aventis) in the years 2012 and 2013 containing 15 μg/strain of 
the A/California/7/2009 (H1N1)pdm09-like virus, A(H3N2) 
virus antigenically like the cell-propagated prototype virus 
A/Victoria/361/201 (H3N2)-like virus, and the B strains: 
B/Wisconsin/1/2010-like virus and B/Massachusetts/2/2012-like 
virus strains, respectively. In 2015, the vaccine contained the 
same H1N1 strain together with A/Switzerland/9715293/2013 
(H3N2)-like virus and B/Phuket/3073/2013-like virus.
clinical samples
Serum was obtained from whole blood collected both pre-
vaccination (day 0) and post-vaccination day 28 ±  3  days for 
serological assays. Briefly whole blood was collected in 8  ml 
Vacuette (Z Serum Sep Clot Activator) tubes, allowed to clot 
for 30 min at room temperature and kept at +4°C for up to 4 h 
before centrifugation at 2500 RCF við +4°C. Serum was collected, 
aliquoted, and kept at −80°C until analyzed by VisMederi (Siena, 
Italy).
Mn assay
The MN assay was modified from a previously described proce-
dure (15); and carried out in VisMederi laboratories. This method 
is based on capability of live virus to infect and replicate in cells, 
producing cytopathic effect (CPE) in the cell culture substrate, 
which is prevented by neutralizing antibodies contained in serum 
of vaccine subjects.
Influenza live virus A/California/07/2009 was egg propa-
gated by VisMederi and used in the assay at the concentra-
tion of 200 TCID50/100 μl [50% tissue culture infective dose 
(TCID50)].
Positive and negative control sera were included in each 
run, as well as a back titration plate for virus titration check. 
In particular, antisera used were specific for each strain tested, 
purchased from NIBSC; depleted serum was supplied by Sigma 
Aldrich (Serum minus IgA/IgM/IgG, S5393).
Each heat-inactivated serum twofold diluted in microtiter 
plates, starting from a 1:10, was incubated with a same volume 
of virus solution (200TCID50/100 μl) for 1  h at 37°C and 5% 
CO2. Then 100 µl of MDCK (Madin-Darby Canine Kidney) cell 
suspension was added to the virus-sera mixture at the concentra-
tion of 2 × 105/ml; then plates were incubated at 37°C and 5% 
CO2 for 5 days. Under optical microscope each wells was assessed 
for the presence of CPE (complete destruction of the cell layer 
in the well or the presence of holes in the cell layer, surrounded 
by destroyed cells), discriminating “infected” and “protected” 
wells. The total number of infected wells of each serum duplicate 
was used to calculate the MN titer of each serum sample by 
Spearman−Karber formula (16). Indicative seroprotection rate 
was defined as percentage of vaccine recipients with serum MN 
titer ≥20 after vaccination.
hai assay
The HAI measurement was carried out in agreement with Vis-
Mederi procedures; using viral antigens, provided by NIBSC, 
diluted at the standard concentration of 160 hemagglutinating 
units (HAU)/ml and correctness of antigen dilution was checked 
out through a back titration in every test. Serum samples were 
treated with receptor destroying enzyme provided by Denka 
Seiken, in a ratio of 1:3, during overnight incubation at 37°C, and 
heat inactivated for 1 h at 56°C. Twofold serial dilutions starting 
from 1:10 were performed for each serum in duplicate in “V” 
bottomed 96-well plates. The antigen solution (4  HAU/25 μl) 
was added to each serum dilution and plates were incubated for 
1 h at room temperature. A 0.35% solution of turkey red blood 
cells was added to each wells and plates were incubated for 1 h 
at room temperature (17). The HA protein is able to agglutinate 
red blood cells due to its binding affinity to surface glycoprotein 
of erythrocytes, and antibodies may interfere with this bind-
ing recognizing the virus antigen; this phenomenon produces 
an inhibition of the hemagglutination resulting in a change in 
the appearance of the well (18). The read out was performed 
by naked eye, distinguishing between the presence of hemag-
glutination and inhibition of it. The HAI titer was calculated as 
the reciprocal value of the highest serum dilution in which the 
hemagglutination was still inhibited. Seroprotection rate was 
defined as percentage of vaccine recipients with serum HAI titer 
≥40 after vaccination.
statistical analysis
Generalized linear regression was used to test the associations 
of log-transformed post-vaccination HAI or MN titers, FC, and 
seroprotection with various traits. The post-vaccination titer and 
FC were corrected for age, gender, pre-vaccination titer, year of 
immunization, and vaccination status (see post-vaccination titer 
model in Table S2 in Supplementary Material). Seroprotection 
was corrected for age, gender, year of immunization, and vac-
cination status (Table S5 in Supplementary Material). Age was 
split into five equal-sized groups. Vaccination status was split into 
three groups; one previous influenza vaccination, more than one 
previous influenza vaccination, and no previous influenza vacci-
nation or information missing. To account for heteroscedasticity 
weighted least squares was used. Correlations between HAI and 
MN derived log-transformed titers were performed using linear 
regression. Statistical analysis was performed using the comput-
ing environment R (19).
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resUlTs
Overall influenza Vaccine responses
A total of 1,852 individuals (46% men and 54% women) at the 
age of 20–103 years (Table 1) that received influenza vaccination 
and participated in the study had both pre- and post-vaccination 
HAI titers for all three vaccine strains available for analysis. 
In addition, MN titer was measured for the whole study group 
for H1N1 and for a subset of 336 for H3N2 and B strains. Overall 
seroprotection (HAI ≥ 40) rates post-vaccination for the three 
study years (2012, 2013, and 2015) were 93% (H1N1), 95% 
(H3N2), and 65% (B strain), with the lowest seroprotection rate 
observed in 2015 for all three strains 90% (H1N1), 93% (H3N2), 
and 33% (B strain). Highest median (25th–75th quantiles) HAI 
post-vaccination titer across the entire study group was observed 
for the H3N2; 226 (113–453) followed by H1N1; 160 (80–320) 
and B; 40 (6–113). MN titer of 20 measured by CPE has been 
suggested to be predictive of protection and correspond to an 
HAI titer of 40 (20). Using MN ≥ 20 as definition of indicative 
MN seroprotection, we observed overall seroprotection rate 
of 63%, ranging from 60% (year 2013) up to 67 (year 2012). 
There was a significant difference in HAI post-vaccination titer 
between the three vaccination years for all three strains (H1N1 
P = 1.4 × 10−20, H3N2 P = 0.011, B P = 4.7 × 10−95). Similarly, 
the H1N1 MN post-vaccination titer differed between years 
(P = 1.6 × 10−4, Table 1).
Previous humoral influenza Virus 
immunity strongly affects influenza 
Vaccine responses
We tested the association of influenza virus-specific pre-vaccination 
immunity status with vaccine responses. Pre-vaccination HAI 
titers associated with FC of post-vaccination HAI titers for 
all strains tested, i.e., high-pre-HAI titer resulting in less fold 
increase in post-vaccination HAI titer (H1N1 P =  1.1 ×  10−99, 
H3N2 P = 1.5 × 10−89, B P = 2.1 × 10−57; Figure 1A), although 
post-vaccination HAI titer itself was positively associated with 
pre-vaccination titer (H1N1 P = 1.4 × 10−147, H3N2 P = 1.0 × 10−123, 
B P  =  4.5  ×  10−157; Figure 1B; Table S2 in Supplementary 
Material). Pre-vaccination titer of HAI explains 27, 24, 19% of 
the variance in HAI post-vaccination titer and 21, 18, and 12% of 
the variance in FC for H1N1, H3N2, and B strains, respectively 
(Table S3 in Supplementary Material). Furthermore, FC of MN 
titers (H1N1) associated strongly with pre-vaccination titers 
(P = 8.6 × 10−30; Figure 1C). Similar association was observed 
for the pre-vaccination titer and FC of MN titer of the small 
subsets (n = 336); Table S4 in Supplementary Material measured 
for H3N2 (P = 1.4 × 10−8) and B strains (P = 2.6 × 10−4). Similar 
to the HAI titer, pre-vaccination MN titer was positively associ-
ated with post-vaccination MN titer (P = 2.1 × 10−159; Figure 1D) 
with the pre-vaccination titer explaining 29% of the H1N1 post-
vaccination titer variance (Table S3 in Supplementary Material).
Vaccinees reporting to have had more than one previous 
influenza vaccination (n = 1,418) had a lower post-vaccination 
titer for all strains than those who reported to have only had 
one (n =  106) previous influenza vaccination [HAI for H1N1 
P =  2.32 ×  10−8, H3N2 P =  3.26 ×  10−15, B P =  9.39 ×  10−7 
(Figure 2A), and MN for H1N1 P = 3.1 × 10−12; Figure 2B; Table 
S2 in Supplementary Material]. There was no significant differ-
ence in HAI seroprotection rate between those receiving one or 
more than one vaccination for H1N1 (P = 3.6 × 10−1) and H3N2 
(P =  6.1 ×  10−1). However, those that received more than one 
vaccination had reduced HAI seroprotection rate for the B strain 
(3.9 × 10−3) as well as for MN seroprotection rate for the H1N1 
(4.6 × 10−6) (Table S5 in Supplementary Material), using 1:20 MN 
titer as a cut-off for seroprotection (20).
Taken together, prior influenza virus-specific antibody levels, 
induced upon influenza virus infection and/or vaccination, 
strongly affect the vaccine-induced humoral response with the 
pre-vaccination titer explaining roughly 19–29% of the variance 
in post-vaccination titer.
age strongly affects influenza Vaccine 
responses, But gender Does not
We tested the effect of age and gender on response to vaccination, 
after adjusting for pre-vaccination titers and year of immuniza-
tion. Post-vaccination HAI titer went down with age for all three 
vaccine strains (H1N1 P =  1.5 ×  10−15, H3N2 P =  1.1 ×  10−9, 
B P = 2.2 × 10−21; Figure 3A). Age was found to explain 3, 2, and 
2% of the variance in post-vaccination titers for H1N1, H3N2, 
B strains, respectively (Table S3 in Supplementary Material).
Hemagglutination inhibition seroprotection rate follow-
ing vaccination was also reduced with increasing age for two 
out of three strains (H1N1 P =  5.9  ×  10−7, H3N2 P >  0.05, 
B P = 4.6 × 10−9; Figure 3B). The youngest age group (20–37 YoA) 
had higher post-vaccination titers than any of the other age 
groups and the difference was most evident when compared with 
the oldest age group (63–103 YoA) (Table S2 in Supplementary 
Material).
Microneutralization titer for H1N1 also showed that increas-
ing age associated with decrease in both post-vaccination titer 
(P =  5.4 ×  10−20; Figure 3C) and indicative seroprotection rate 
(P = 8.3 × 10−31; Figure 3D), similar to what was observed for the 
HAI titers. Age explained 3% of the variance in H1N1 post-vacci-
nation MN titers. Similar association was observed with age for the 
subset (n = 336; Table S4 in Supplementary Material) measured 
for H3N2 (P = 1.9 × 10−4) and B (P = 9.4 × 10−4) strains (data not 
shown). Interestingly, the effect of age on the MN titer was even 
more pronounced than on HAI titer indicating that the MN titer 
more specifically captures the age-related reduced neutralizing 
functionality of antibodies than the HAI titer (Figures  3A,C). 
No significant effects of gender on either post-vaccination HAI or 
MN titers or seroprotection rates were observed among all vac-
cinees for any of the strains tested (Figure S1 in Supplementary 
Material) nor among the elderly vaccinees (data not shown).
Medication and Underlying Diseases  
have small effects on Vaccine responses 
in the Whole group of Vaccinees
Underlying health conditions as well as medications with 
known immunomodulatory effects have been proposed to affect 
influenza vaccine responses (4–7, 21). We received data from 
TaBle 1 | Overview of cohort and main parameters for the influenza vaccine study in years 2012, 2013, and 2015.
characteristics 2012 2013 2015 Whole cohort
Total subjects (%) 565 (31) 711 (38) 576 (31) 1,852
age
Mean 55 51 47 51
Median (25th–75th quantile) 55 (46–63) 50 (39–61) 47 (38–56) 51 (40–60)
Range 20–103 21–95 21–70 20–103
gender
Male (%) 188 (33) 348 (49) 307 (53) 843 (46)
Female (%) 377 (67) 363 (51) 269 (47) 1,009 (54)
serological vaccine response
h1n1 (hai)
Pre-titer mean 131 115 79 109
Pre-titer median (25th–75th quantile) 57 (20–160) 67 (24–160) 40 (16–80) 57 (20–160)
Post-titer mean 319 290 180 264
Post-titer median (25th–75th quantile) 160 (80–453) 190 (113–320) 160 (80–160) 160 (80–320)
Fold increase mean 12 10 9 10
Fold increase median (25th–75th quantile) 2 (1–8) 2 (1–6) 2 (1–4) 2 (1–6)
Seroprotection rate pre-vaccination 63 70 65 67
Seroprotection rate post-vaccination 94 96 90 93
h3n2 (hai)
Pre-titer mean 135 155 54 117
Pre-titer median (25th–75th quantile) 80 (14–160) 80 (40–190) 40 (5–80) 57 (20–160)
Post-titer mean 366 436 280 366
Post-titer median (25th–75th quantile) 320 (160–640) 320 (160–640) 160 (80–320) 226 (113–453)
Fold increase mean 16 13 17 15
Fold increase median (25th–75th quantile) 3 (1–8) 2 (1–8) 4 (2–16) 3 (2–11)
Seroprotection rate pre-vaccination 62 78 52 65
Seroprotection rate post-vaccination 94 98 93 95
B (hai)
Pre-titer mean 68 24 12 34
Pre-titer median (25th–75th quantile) 40 (10–80) 5 (5–28) 5 (5–5) 5 (5–40)
Post-titer mean 225 66 29 103
Post-titer median (25th–75th quantile) 160 (80–320) 40 (13–80) 5 (5–40) 40 (6–113)
Fold increase mean 11 7 4 7
Fold increase median (25th–75th quantile) 4 (1–8) 2 (1–8) 1 (1–3) 2 (1–8)
Seroprotection rate pre-vaccination 51 24 11 28
Seroprotection rate post-vaccination 88 72 33 65
h1n1 (Mn)
Pre-titer mean 24 19 23 22
Pre-titer median (25th–75th quantile) 14 (7–28) 10 (7–20) 14 (7–28) 14 (7–28)
Post-titer mean 54 44 47 48
Post-titer median (25th–75th quantile) 28 (14–57) 28 (14–56) 28 (14–56) 28 (14–56)
Fold increase mean 4 3 3 3
Fold increase median (25th–75th quantile) 2 (1–4) 1 (1–4) 2 (1–2) 1 (1–4)
Seroprotection rate pre-vaccination 32 27 31 30
Seroprotection rate post-vaccination 67 60 61 63
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the Directorate of Health Prescription Database on prescrip-
tions/dispensing of various immunomodulating agents for all 
vaccinees from 2003 until the time of vaccination. The medica-
tion included lipid modifying agents (statins both fermented 
and synthetic), non-steroidal anti-inflammatory drugs, and 
asthma/allergy drugs (Table S1 in Supplementary Material). 
We used strict criteria for the prescribed medicines, dispensed 
0–3 months before vaccination, to increase the likelihood of the 
subjects actually taking the medication at the time of vaccination. 
Vaccine responses did not show significant association with any 
of the medications studied here (Table 2). Neither was there a 
significant effect of any of the medications on vaccine responses 
among vaccinees over 65 YoA (data not shown).
We received discharge diagnosis from Landspitali, the 
National University Hospital of Iceland for all the vaccinees (dated 
from 1990), which were used in addition to the existing data at 
deCODE. The effect of autoimmune disease and asthma and/or 
allergic diseases on vaccine responses was tested. Subjects with 
asthma/allergic diseases had lower post-vaccination HAI titer for 
H3N2 strain than the rest of the vaccinees, which was nominally 
significant (β = −0.167, P =  0.024). No effects of autoimmune 
diseases on the post-vaccination HAI titers were observed 
(Table  3). Neither did autoimmune or asthma/allergic diseases 
affect vaccine responses among vaccinees over 65 YoA (data not 
shown). Self-reported general health status including information 
on: hospitalization due to infections, underlying diseases, and use 
of prescribed medicines was assessed through questionnaire data 
completed by 87% of vaccines. However, none of those parameters 
associated significantly with post-vaccination HAI titers when 
corrected for number of statistical tests (data not shown).
FigUre 1 | High-pre-vaccination titer strongly decreases antibody response upon influenza virus vaccination. Boxplot showing log hemagglutination inhibition (HAI) 
fold increase for H1N1, H3N2, and B (y-axes) vs. corresponding pre-vaccination titer (on x-axes) (a). Log H1N1, H3N2, and B HAI post-vaccination titer (y-axes) vs. 
corresponding pre-vaccination titer (x-axes) (B). Log H1N1 microneutralization (MN) fold increase (y-axes) vs. pre-vaccination MN titer (x-axes) (c) and log H1N1 MN 
post-vaccination titer vs. H1N1 pre-vaccination titer (D). Line within the boxplots indicate median value and the top and the bottom correspond to the 25th (Q1) and 
75th (Q3) quantiles. The whiskers of the box plots are located at Q1 − 1.5 interquartile range (IQR) and Q3 + 1.5 IQR. P-values for association between fold change 
and pre-vaccination titer (a,c) and post-vaccination titers and pre-vaccination titer (B,D) are shown. Age, measurement date, previous influenza vaccination status, 
and gender were included as covariates.
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Therefore, our data indicate that for this large heterogeneous 
group of vaccinees of a broad age range medications and under-
lying diseases had no or minimal effects on influenza vaccine 
responses although asthma/allergic disease warrants further 
investigation in a controlled clinical study.
DiscUssiOn
Here, we report seasonal influenza vaccine-induced antibody 
responses of Icelanders of wide age range and health status. The 
strongest association with vaccine-induced HAI responses was 
observed for the level of pre-vaccination HAI titer, thus those 
with high-pre-vaccination HAI titer did not show fold increase in 
post-vaccination HAI titer to the same extent as those with low-
pre-vaccination HAI titer. The same was observed for the more 
functional MN titer. Large part of the FC variance (12–21%) was 
explained by the pre-vaccination titer. However, post-vaccination 
titer itself strongly associated positively with pre-vaccination 
titer, meaning that even if those with high-pre-vaccination titer 
showed less fold increase than those with low-pre-vaccination 
titer, their post-vaccination HAI/MN titer was overall higher. 
Pre-vaccination titer explained a large part of the variance in 
post-vaccination titer, or 19–29% depending on the viral strain 
and assay used for antibody measurements.
Our results on this population-based heterogeneous group of 
vaccinees are in line with previous reports from smaller studies 
showing correlation between pre-existing antibody levels to a 
given strain and reduced humoral immune responses upon vac-
cination with the same strain (22–25). The most plausible expla-
nation as to how pre-existing strain-specific antibodies adversely 
affect subsequent vaccine responses is that they bind and mask 
viral epitopes in a vaccine containing a homologous strain, 
supported by the fact that high-pre-existing antibody levels also 
correlate with activation of fewer strain-specific plasmablasts, 
FigUre 2 | Multiple previous influenza virus vaccination associate with 
reduced hemagglutination inhibition (HAI) titer. Log HAI for H1N1, H3N2, and 
B strain (a) and log H1N1 microneutralization (MN) (B) post-vaccination titer 
for vaccinees that reported to have had one previous influenza vaccination or 
more than one previous influenza vaccination. Line within the boxplots 
indicate median value and the top and the bottom correspond to the 25th 
(Q1) and 75th (Q3) quantiles. The whiskers of the box plots are located at 
Q1 − 1.5 interquartile range (IQR) and Q3 + 1.5 IQR. P-values for association 
between post-vaccination titers and previous influenza vaccinations are 
shown. Pre-titer, age, measurement date, and gender were included as 
covariates.
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and vaccine-induced memory B cells (22). However, our results 
demonstrate that when effect on vaccine response is evaluated 
the readout, fold increase vs. post-vaccination titer, must be 
considered. The effect of lower HAI/MN titer fold increase upon 
repeated vaccinations on vaccine efficacy has been debated, 
ranging from less efficacy (26) to reduced serious influenza 
disease and better efficacy (27–29) reported for individuals 
receiving repeated influenza vaccinations. It has been proposed 
that antigenic distances between annual vaccine strains on one 
hand and the epidemic strains on the other hand might explain 
those discrepancies (30). Pre-existing immunity has also been 
shown to affect the type of antibodies induced upon vaccina-
tion with low-pre-existing immunity to H1N1 pandemic strain 
inducing more broadly protecting HA stalk-specific antibodies, 
whereas with high-pre-vaccination immunity mainly strain-
specific antibodies aimed at the HA head were induced (31). 
We could not distinguish between stalk- or head-specific anti-
bodies in our MN measurements and based on previous publica-
tions claiming that antibodies toward the stalk domain appear to 
neutralize less potently than antibodies directed to the HA head 
domain (32, 33) it is likely that our MN measurements are mainly 
picking up head-specific antibodies. Future studies addressing 
the role of pre-existing immunity on antibody-dependent cell-
mediated cytotoxicity (ADCC) of cells infected with homologous 
or heterologous influenza virus strains would be highly interest-
ing as protective role of stalk binding antibodies has been linked 
with FcγR-mediated ADCC (11). Our study was not designed to 
evaluate vaccine efficacy. However, given that almost one-third of 
the post-vaccination variance (both HAI and MN) is explained 
by the level of pre-vaccination titers in our study and the fact that 
the current H1N1 strain used in seasonal influenza vaccines did 
not change for years following the 2009–2010 pandemic despite 
considerable antigenic drift in the epidemic strains of this same 
period (34), we believe it is high time to re-evaluate whether 
repeated vaccinations with the same strain are beneficial for the 
vaccine efficacy or not. However, it should be noted that there was 
no difference in HAI seroprotection rate for the H1N1 and H3N2 
strains between those that had received only one compared with 
more than one previous vaccinations, although reduced HAI and 
indicative MN seroprotection levels were observed for the B and 
H1N1 strain, respectively, despite higher post-vaccination titer 
for all strains. The arbitrary cut-off we used here for indicative 
MN seroprotection is based on a previous publication using 
the same cytopathic lab test for H5N1 (20), which has not been 
validated for other influenza virus strains and might not reflect 
seroprotection levels for the H1N1 strain used in this study.
Fold change is most commonly used to evaluate vaccine 
responses to influenza viruses and many other pathogens. Our 
results clearly show that FC can be misleading for evaluation of 
vaccine responses in vaccine/virus experienced individuals and 
strongly suggests that overall post-vaccination HAI or MN titers 
adjusted for pre-vaccination titer are more relevant and should 
also be considered. This is in line with new guidelines from the 
European medicines agency on licensing of novel influenza vac-
cines in Europe that emphasize the importance of quantifying 
functional antibodies in addition to the HA antibody response. 
Furthermore, the guidelines no longer rely on the pre-defined 
TaBle 3 | Effect of underlying disease on post-hemagglutination inhibition (HAI).
h1n1 (hai) h3n2 (hai) B (hai) h1n1 (Mn)
Underlying disease (n) β P-value β P-value β P-value β P-value
Asthma and allergy (187) −0.033 6.2 × 10−1 −0.16 2.0 × 10−2 −0.052 4.7 × 10−1 −0.020 9.7 × 10−1
Autoimmune disease (125) −0.056 4.9 × 10−1 −0.14 1.1 × 10−1 −0.028 7.5 × 10−1 −0.088 2.2 × 10−1
Significant values presented in bold.
FigUre 3 | Strong association between age and both hemagglutination inhibition (HAI) and neutralization post-vaccination titer and seroprotection rate. Log HAI 
titer at different age gaps for all three serotypes (a). HAI seroprotection rate (HAI > 40) pre- and post-vaccination at different age gaps (B). Log microneutralization 
(MN) titer at different age gaps for H1N1 strain (c). Indicative MN seroprotection rate for H1N1 (MN > 20) pre- and post-vaccination at different age gaps (D). Line 
within the boxplots in (a,c) indicate median value and the top and the bottom correspond to the 25th (Q1) and 75th (Q3) quantiles. The whiskers of the box plots 
are located at Q1 − 1.5 interquartile range (IQR) and Q3 + 1.5 IQR. P-values for association between post-vaccination titer and age (a,c) and seroprotection rate 
and age (B,D) are shown. Pre-titer, age, measurement date, previous influenza vaccination status, and gender were included as covariates.
TaBle 2 | Effect of medication 0–3 months before vaccination on post-hemagglutination inhibition (HAI).
h1n1 (hai) h3n2 (hai) B (hai) h1n1 (Mn)
Medication (n) β P-value β P-value β P-value β P-value
Antiparasitic products (21) −0.026 8.9 × 10−1 −0.25 2.4 × 10−1 −0.16 4.3 × 10−1 0.049 7.7 × 10−1
Statins all (215) −0.024 7.1 × 10−1 −0.075 2.9 × 10−1 −0.0089 9.0 × 10−1 0.022 7.0 × 10−1
Statins fermented (120) −0.099 2.4 × 10−1 −0.1 2.4 × 10−1 0.06 5.1 × 10−1 −0.0082 9.1 × 10−1
Statins synthetic (97) 0.075 4.2 × 10−1 −0.018 8.5 × 10−1 −0.065 5.2 × 10−1 0.055 5.0 × 10−1
Biologics (32) −0.21 1.8 × 10−1 −0.12 4.7 × 10−1 −0.26 1.2 × 10−1 −0.088 5.2 × 10−1
NSAID (144) 0.082 2.8 × 10−1 0.12 1.3 × 10−1 0.052 5.3 × 10−1 0.043 5.2 × 10−1
Asthma and Allergy (229) −0.041 5.0 × 10−1 0.0076 9.1 × 10−1 −0.016 8.1 × 10−1 0.045 4.0 × 10−1
Inhaled corticosteroids (143) −0.043 5.7 × 10−1 0.019 8.1 × 10−1 −0.04 6.2 × 10−1 0.032 6.3 × 10−1
Any medication (543) −0.014 7.6 × 10−1 −0.0022 9.6 × 10−1 −0.022 6.5 × 10−1 0.043 2.8 × 10−1
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protective threshold based on serological assays (GMT increase, 
seroconversion, and seroprotection based on HAI  ≥  1:40), 
declaring that this was not the most informative approach for 
different subgroups of vaccinees (35). The youngest age group 
(20–37 YoA) had the highest HAI post-vaccination titer (adjusted 
for pre-vaccination titers, gender, year of immunization, and 
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vaccination status) and seroprotection rates for all three vaccine 
strains. Previously, age-associated vaccine responses have primarily 
been reported for young (<65 YoA) vs. elderly (≥65 YoA) sub-
jects, whereas differences in responses within the younger adult 
vaccination groups has not been extensively studied. Our data 
are in line with a recent report of significantly different influenza 
vaccine-induced transcriptomic responses of people older than 
35  YoA compared with younger adults (36), indicating that 
changes in influenza vaccine responses occur much earlier in life 
than frequently reported. MN that measures functional antibod-
ies seems to better capture the effect of age on vaccine responses 
than HAI titer, observed in a substantial decrease in the MN titer 
in vaccinees at 56–62 YoA, and again in those aged 63–103 years 
old. Still, age explains only 2–3% of the overall variance in post-
vaccination titers, corresponding to 10% of what is explained 
by pre-vaccination antibody levels. It was recently reported 
that only two previous influenza vaccinations were needed to 
account for the entire differences in influenza vaccine responses 
observed between the young and elderly groups (37). However, 
we observed significant effects of age on vaccine responses even 
when we corrected for vaccination status (if subjects had received 
only one or more than one previous vaccination) indicating that 
in our study the age effect is not entirely based on vaccine history.
The strength of this study is presented by the broad age 
range and the fact that vaccinees were not selected into the 
study, but all individuals offered vaccination at two nursing 
homes and over 70 workplaces, including health institutions 
and schools, were invited to participate. The vaccinees thus 
represent a snapshot of the Icelandic population that gets an 
annual influenza vaccination, irrespective of age and health 
status. This, unfortunately, also means that the study is under-
powered for detecting small effects in various subgroups, such 
as specific disease groups, but rather gives indications for 
interesting future research.
Overall, our data do not point toward major effects of under-
lying diseases and/or medication (based on prescription and 
dispensing within 3  months) on influenza vaccine responses. 
Out of the underlying diseases tested, vaccinees with diagnosed 
asthma and/or allergic diseases were the only ones showing a 
trend toward lower post-vaccination HAI titers. The effects of 
influenza vaccination in asthma patients has mainly been evalu-
ated on safety and efficacy with inconsistent results that might 
be due to the different cohorts, vaccines, and methodology 
applied (38, 39).
Chronic intake of fermentation derived and synthetic statins 
have previously, been linked with lower influenza vaccine 
responses and reduced effectiveness in an elderly cohort (21, 40). 
Therefore, we looked at the association of synthetically and 
fermentation derived statins on vaccine-induced HAI post-
vaccination titer but found no significant association of vaccine 
responses with either class of statins or both classes combined. 
This could be due to the low number of elderly people among our 
vaccinees (n = 261) compared with the previous study of vaccinees 
≥65 YoA (n = 6,961) (21). We also tested the effect of statins in 
our ≥65 YoA vaccinees separately where 26% of the 261 subjects 
were on statins but we found no significant association with vac-
cine responses there either (data not shown). Furthermore, our 
analysis is based on prescribed/dispensed statins and we did not 
have as detailed information on statin intake as in the previous 
publication (daily statin intake ≥28 days before through 22 days 
after vaccination).
Taken together, our results show that in the whole study group 
influenza virus-specific pre-vaccination immune status is the 
major factor affecting TIV vaccine responses, followed by age. 
None of the other variables tested had significant effects, consid-
ering the number of tests performed, although vaccine responses 
in asthma/allergic patients tended to be reduced and could be an 
interesting future research area.
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